Clinical trials
Phase 1 Scleroderma, Systemic trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
32 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2002 | 1 |
| 2003 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 7 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 7 |
| Recruiting | 7 |
| Terminated | 7 |
| Not yet recruiting | 4 |
| Active, not recruiting | 4 |
| Enrolling by invitation | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2 |
| Medical University of South Carolina | 2 |
| AbelZeta Inc. | 1 |
| Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 1 |
| Adicet Therapeutics | 1 |
| Allogene Therapeutics | 1 |
| Amgen | 1 |
| AstraZeneca | 1 |
| Baylor College of Medicine | 1 |
| Bristol-Myers Squibb | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Scleroderma, Systemic | 32 |
| Lupus Erythematosus, Systemic | 16 |
| Autoimmune Diseases | 13 |
| Scleroderma, Diffuse | 13 |
| Lupus Nephritis | 12 |
| Myositis | 10 |
| Dermatomyositis | 8 |
| Arthritis, Rheumatoid | 6 |
| Polymyositis | 3 |
| Sjogren's Syndrome | 3 |
Trials
Showing 1 to 25 of 32. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.